We use science to save lives, and so can you. We are currently recruiting for a Scientific Assistant to join the Analytical Development and Quality Control (ADQC) team. The purpose of this role is to provide essential laboratory activities and services to support the ADQC department. Our Analytical Services Group supports the development of products through analytical testing to facilitate manufacturing and process development, ensuring appropriate quality controls and use of analytics. Your responsibilities in this role would be: · To perform routine monitoring of controlled temperature units within ASG CL2 laboratories · To raise engineering requests and to chaperone engineers whilst they are servicing/repairing analytical instruments. · To generate and review equipment files for basic pieces of equipment to meet Good Manufacturing Practices (GMP) standards · To clean and maintain the laboratory equipment and facilities · Calibrate the pH meter and balance as required ready for analytical testing · To operate the autoclave and dispose of waste materials as required · Perform stock checks of consumables, media, solutions, buffers used by Scientists to ensure work activities are maintained. · Assist the team to ensure the CL2 laboratory suites meet regulatory compliance · To raise LMT work requests and assist LMT if required · Assist in maintaining the health and safety compliance as applicable to a CL2 laboratory facility We are looking for: · Level 2 - GCSE English and Maths · Knowledge and understanding of efficient and effective laboratory working practices · Ability to read, write legibly, and perform basic maths · Proficiency in Microsoft Excel, Word, and Outlook · Ability to challenge current practices and suggest new ideas · Excellent communication skills and ability to communicate clearly with Scientists and Managers · Organizational skills and service-oriented mindset · Able to listen to instructions and follow them · Demonstrate a willingness to learn About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialization. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: · Highly competitive total reward packages · Wellbeing programmes · Development opportunities · Welcoming, friendly, supportive colleagues · A diverse and inclusive working environment · Our values are: Responsible, Responsive, Resilient, Respect · State-of-the-art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives. LI-SCM1 Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.